Research programme: transferrin receptor targeting therapeutics - Apellis Pharmaceuticals
Latest Information Update: 12 Jul 2022
At a glance
- Originator Apellis Pharmaceuticals
- Class Protein-drug conjugates
- Mechanism of Action Transferrin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurological disorders